Skip to content

Clinical trials

Phase 3 Schizophrenia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Schizophrenia Phase: Phase 3 Clear all

410 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
200110
200210
200315
200442
200533
200628
200720
200829
20097
201025
201123
201215
201319
20149
20158
201612
20179
20183
201913
20205
202112
202210
20238
20245
202512
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed311
Terminated43
Recruiting22
Unknown status19
Withdrawn7
Not yet recruiting4
Active, not recruiting3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Otsuka Pharmaceutical Development & Commercialization, Inc.39
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.32
AstraZeneca20
Organon and Co18
H. Lundbeck A/S16
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.13
Sumitomo Pharma America, Inc.13
Alkermes, Inc.12
Karuna Therapeutics, Inc., a Bristol Myers Squibb company11
Eli Lilly and Company10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Schizophrenia410
Psychotic Disorders85
Mental Disorders18
Bipolar Disorder15
Cognitive Dysfunction6
Psychomotor Agitation6
Major Depressive Disorder5
Metabolic Syndrome5
Anxiety Disorders4
Cognition Disorders4

Trials

Showing 1 to 25 of 410. Each trial links to its page on Pharma Observatory.

310 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.